drugset / Trial / NCT00045708

A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas

NCT00045708

Phase 1/2 Completed 57 enrolled National Cancer Institute (NCI)
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase I/II trial is studying the side effects and best dose of ixabepilone and how well it works in treating patients with recurrent glioma.

Timeline

Start
2002-10
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixabepilone Small molecule Intravenous